期刊
DIABETES
卷 70, 期 6, 页码 1334-1346出版社
AMER DIABETES ASSOC
DOI: 10.2337/db20-0845
关键词
-
资金
- American Diabetes Association [1-19-PMF-022]
- National Institutes of Health Graduate Training Program in Dynamic Aspects of Chemical Biology grant from the National Institute of General Medical Sciences [T32GM008545]
- JDRF [2-SRA-2017-312-S-B]
- Office of the Director, National Institutes of Health [S10OD020056]
- National Center for Research Resources award [S10RR027050]
- Diabetes Research Center grant [P30DK063608]
Utilizing soluble antigen arrays (SAgAs) as a platform for antigen-specific immunotherapy (ASIT) can enhance the treatment efficacy of T1D while mitigating the risks of anaphylaxis.
Antigen-specific immunotherapy (ASIT) offers a targeted treatment of autoimmune diseases that selectively inhibits autoreactive lymphocytes, but there remains an unmet need for approaches that address the limited clinical efficacy of ASIT. Soluble antigen arrays (SAgAs) deliver antigenic peptides or proteins in multivalent form, attached to a hyaluronic acid backbone using either hydrolysable linkers (hSAgAs) or stable click chemistry linkers (cSAgAs). They were evaluated for the ability to block spontaneous development of disease in a nonobese diabetic mouse model of type 1 diabetes (T1D). Two peptides, a hybrid insulin peptide and a mimotope, efficiently prevented the onset of T1D when delivered in combination as SAgAs, but not individually. Relative to free peptides administered at equimolar dose, SAgAs (particularly cSAgAs) enabled a more effective engagement of antigen-specific T cells with greater persistence and induction of tolerance markers, such as CD73, interleukin-10, programmed death-1, and KLRG-1. Anaphylaxis caused by free peptides was attenuated using hSAgA and obviated using cSAgA platforms. Despite similarities, the two peptides elicited largely nonoverlapping and possibly complementary responses among endogenous T cells in treated mice. Thus, SAgAs offer a novel and promising ASIT platform superior to free peptides in inducing tolerance while mitigating risks of anaphylaxis for the treatment of T1D.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据